Merck Animal Health Completes Acquisition of U.S. Rights to SENTINEL® Brand of Combination Parasiticides for Companion Animals
July 02 2020 - 2:00AM
Business Wire
Further Solidifies Merck Animal Health’s
Position in the U.S. Companion Animal Category with Comprehensive,
Continuous Parasite Protection
Complements Merck Animal Health’s Broad
Portfolio of Vaccines and Pharmaceuticals
Merck Animal Health, known as MSD Animal Health outside the
United States and Canada, a division of Merck & Co., Inc.,
Kenilworth, N.J., USA (NYSE:MRK), today announced the completion of
its previously announced acquisition of the U.S. rights to
SENTINEL® FLAVOR TABS® and SENTINEL® SPECTRUM® Chews in the
Companion Animal category from Virbac (NYSE Euronext:VIRP).
Comprehensive parasite protection is an essential part of canine
overall health and well-being. “Our veterinary medicines, including
parasiticides, and vaccines continue to transform the animal health
industry and further solidify our position in the U.S. Companion
Animal category,” said Rick DeLuca, president, Merck Animal Health.
“The extensive breadth and depth of our product portfolio enhances
our offerings of comprehensive pet care solutions, which provide a
full range of complementary solutions for our customers to improve
the health and well-being of animals and the people who care for
them.”
About Merck Animal Health
For more than a century, Merck, a leading global
biopharmaceutical company, has been inventing for life, bringing
forward medicines and vaccines for many of the world’s most
challenging diseases. Merck Animal Health, a division of Merck
& Co., Inc., Kenilworth, N.J., USA, is the global animal health
business unit of Merck. Through its commitment to The Science of
Healthier Animals®, Merck Animal Health offers veterinarians,
farmers, pet owners and governments one of the widest ranges of
veterinary pharmaceuticals, vaccines and health management
solutions and services as well as an extensive suite of digitally
connected identification, traceability and monitoring products.
Merck Animal Health is dedicated to preserving and improving the
health, well-being and performance of animals and the people who
care for them. It invests extensively in dynamic and comprehensive
R&D resources and a modern, global supply chain. Merck Animal
Health is present in more than 50 countries, while its products are
available in some 150 markets. For more information, visit
www.merck-animal-health.com or connect with us on LinkedIn,
Facebook, and Twitter at @MerckAH.
About Virbac
Virbac offers veterinarians, farmers and pet owners in more than
100 countries a practical range of products and services for
diagnosing, preventing and treating the majority of diseases while
improving quality of life for animals. With these innovative
solutions covering more than 50 species, Virbac contributes day
after day to shaping the future of animal health.
Forward-Looking Statement of Merck & Co., Inc.,
Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J.,
USA (the “company”) includes “forward-looking statements” within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These statements are
based upon the current beliefs and expectations of the company’s
management and are subject to significant risks and uncertainties.
If underlying assumptions prove inaccurate or risks or
uncertainties materialize, actual results may differ materially
from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general
industry conditions and competition; general economic factors,
including interest rate and currency exchange rate fluctuations;
the impact of the recent global outbreak of novel coronavirus
disease (COVID-19); the impact of pharmaceutical industry
regulation and health care legislation in the United States and
internationally; global trends toward health care cost containment;
technological advances, new products and patents attained by
competitors; challenges inherent in new product development,
including obtaining regulatory approval; the company’s ability to
accurately predict future market conditions; manufacturing
difficulties or delays; financial instability of international
economies and sovereign risk; dependence on the effectiveness of
the company’s patents and other protections for innovative
products; and the exposure to litigation, including patent
litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause
results to differ materially from those described in the
forward-looking statements can be found in the company’s 2019
Annual Report on Form 10-K and the company’s other filings with the
Securities and Exchange Commission (SEC) available at the SEC’s
Internet site (www.sec.gov).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200701005757/en/
Merck Media: Noreen Verbrugge + 1 (973) 937-5450
Noreen.Verbrugge@merck.com
Pam Eisele +1 (267) 305-3558 Pamela.Eisele@merck.com
Merck Investors: Michael DeCarbo + 1 (908) 740-1807
Michael.DeCarbo@merck.com
Merck (NYSE:MRK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2023 to Apr 2024